Foy, Susan P.
Jacoby, Kyle
Bota, Daniela A.
Hunter, Theresa http://orcid.org/0000-0002-6494-1294
Pan, Zheng
Stawiski, Eric
Ma, Yan
Lu, William
Peng, Songming
Wang, Clifford L.
Yuen, Benjamin
Dalmas, Olivier
Heeringa, Katharine
Sennino, Barbara
Conroy, Andy
Bethune, Michael T.
Mende, Ines
White, William
Kukreja, Monica
Gunturu, Swetha
Humphrey, Emily
Hussaini, Adeel
An, Duo
Litterman, Adam J.
Quach, Boi Bryant
Ng, Alphonsus H. C.
Lu, Yue
Smith, Chad
Campbell, Katie M. http://orcid.org/0000-0001-6491-4432
Anaya, Daniel
Skrdlant, Lindsey
Huang, Eva Yi-Hsuan
Mendoza, Ventura
Mathur, Jyoti
Dengler, Luke
Purandare, Bhamini
Moot, Robert
Yi, Michael C.
Funke, Roel
Sibley, Alison
Stallings-Schmitt, Todd
Oh, David Y.
Chmielowski, Bartosz http://orcid.org/0000-0002-2374-3320
Abedi, Mehrdad http://orcid.org/0000-0003-4640-0977
Yuan, Yuan
Sosman, Jeffrey A.
Lee, Sylvia M. http://orcid.org/0000-0002-7425-2230
Schoenfeld, Adam J.
Baltimore, David http://orcid.org/0000-0001-8723-8190
Heath, James R. http://orcid.org/0000-0001-5356-4385
Franzusoff, Alex
Ribas, Antoni http://orcid.org/0000-0003-3669-8458
Rao, Arati V.
Mandl, Stefanie J.
Article History
Received: 16 June 2022
Accepted: 4 November 2022
First Online: 10 November 2022
Competing interests
: S.P.F., K.J., T.H., Z.P., E.S., Y.M., W.L., S.P., C.L.W., B.Y., O.D., K.H., B.S., A.C., M.T.B., I.M., W.W., M.K., S.G., E.H., A.H., D. An, A.J.L., B.B.Q., C.S., D. Anaya, L.S., E.Y.-H.H., V.M., J.M., L.D., B.P., R.M., M.C.Y., R.F., A.S., T.S.-S., A.F., A.V.R. and S.J.M. were employees of PACT Pharma during the conduct of this work. S.P., M.T.B., D.B., J.R.H. and A.R. are scientific co-founders of PACT Pharma. K.M.C. has received consulting fees from PACT Pharma and Tango Therapeutics and is a shareholder in Geneoscopy. D.Y.O. has received research support from Merck, PACT Pharma, the Parker Institute for Cancer Immunotherapy, Poseida Therapeutics, TCR2 Therapeutics, Roche/Genentech and Nutcracker Therapeutics. B.C. has advisory roles with the following companies: Iovance Biotherapeutics, IDEAYA Biosciences, Sanofi, OncoSec, Nektar, Genentech, Novartis and Instil Bio. D.Y.O. has also received research funding from the following companies: Iovance Biotherapeutics, Bristol-Myers Squibb, Macrogenics, Daiichi Sankyo, Merck, Karyopharm Therapeutics, Infinity Pharmaceuticals, Advenchen Laboratories, Idera, Neon Therapeutics, Xencor, Compugen, PACT Pharma, RAPT Therapeutics, Immunocore, Lilly, IDEAYA Biosciences, Tolero Pharmaceuticals, Ascentage Pharma, Novartis, Atreca, Replimune, Instil Bio, Trisalus and Kinnate. J.A.S. reports honorarium from Iovance, Apixogen, Jazz Pharm, and research with BMS, PACT Pharma and Corvus. A.J.S. reports consulting or advising roles to J&J, KSQ Therapeutics, BMS, Enara Bio, Perceptive Advisors, Heat Biologics and Iovance Biotherapeutics. Research funding: GSK (Inst), PACT pharma (Inst), Iovance Biotherapeutics (Inst), Achilles therapeutics (Inst), Merck (Inst), BMS (Inst), Harpoon Therapeutics (Inst). A.R. has received honoraria from consulting with Amgen, CStone, Merck, and Vedanta, is or has been a member of the scientific advisory board and holds stock in Advaxis, Appia, Apricity, Arcus, Compugen, CytomX, Highlight, ImaginAb, ImmPact, ImmuneSensor, Inspirna, Isoplexis, Kite-Gilead, Lutris, MapKure, Merus, PACT Pharma, Pluto, RAPT, Synthekine and Tango, has received research funding from Agilent and from Bristol-Myers Squibb through Stand Up to Cancer (SU2C), and patent royalties from Arsenal Bio. D.A.B., A.H.C.N., Y.L., M.A., Y.Y. and S.M.L. report no conflicts of interest for this work.